304 related articles for article (PubMed ID: 20574050)
21. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Moreaux J; Klein B; Bataille R; Descamps G; Maïga S; Hose D; Goldschmidt H; Jauch A; Rème T; Jourdan M; Amiot M; Pellat-Deceunynck C
Haematologica; 2011 Apr; 96(4):574-82. PubMed ID: 21173094
[TBL] [Abstract][Full Text] [Related]
22. A gene expression signature for high-risk multiple myeloma.
Kuiper R; Broyl A; de Knegt Y; van Vliet MH; van Beers EH; van der Holt B; el Jarari L; Mulligan G; Gregory W; Morgan G; Goldschmidt H; Lokhorst HM; van Duin M; Sonneveld P
Leukemia; 2012 Nov; 26(11):2406-13. PubMed ID: 22722715
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
Agnelli L; Storti P; Todoerti K; Sammarelli G; Dalla Palma B; Bolzoni M; Rocci A; Piazza F; Semenzato G; Palumbo A; Neri A; Giuliani N
Am J Hematol; 2011 Dec; 86(12):E64-6. PubMed ID: 21953534
[TBL] [Abstract][Full Text] [Related]
24. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data.
Sevcikova S; Paszekova H; Besse L; Sedlarikova L; Kubaczkova V; Almasi M; Pour L; Hajek R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):288-93. PubMed ID: 25877407
[TBL] [Abstract][Full Text] [Related]
25. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
[TBL] [Abstract][Full Text] [Related]
26. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Samo AA; Li J; Zhou M; Sun Y; Yang Y; Zhang Y; Li J; van Duin M; Lu X; Fan X
Genes Chromosomes Cancer; 2018 Aug; 57(8):420-429. PubMed ID: 29696703
[TBL] [Abstract][Full Text] [Related]
27. Low-risk identification in multiple myeloma using a new 14-gene model.
Chen T; Berno T; Zangari M
Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
[TBL] [Abstract][Full Text] [Related]
28. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
Moreaux J; Cremer FW; Reme T; Raab M; Mahtouk K; Kaukel P; Pantesco V; De Vos J; Jourdan E; Jauch A; Legouffe E; Moos M; Fiol G; Goldschmidt H; Rossi JF; Hose D; Klein B
Blood; 2005 Aug; 106(3):1021-30. PubMed ID: 15827134
[TBL] [Abstract][Full Text] [Related]
29. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.
Kryukov F; Nemec P; Radova L; Kryukova E; Okubote S; Minarik J; Stefanikova Z; Pour L; Hajek R
J Transl Med; 2016 May; 14(1):150. PubMed ID: 27234807
[TBL] [Abstract][Full Text] [Related]
30. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays.
De Vos J; Thykjaer T; Tarte K; Ensslen M; Raynaud P; Requirand G; Pellet F; Pantesco V; Rème T; Jourdan M; Rossi JF; Ørntoft T; Klein B
Oncogene; 2002 Oct; 21(44):6848-57. PubMed ID: 12360412
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.
Magrangeas F; Nasser V; Avet-Loiseau H; Loriod B; Decaux O; Granjeaud S; Bertucci F; Birnbaum D; Nguyen C; Harousseau JL; Bataille R; Houlgatte R; Minvielle S
Blood; 2003 Jun; 101(12):4998-5006. PubMed ID: 12623842
[TBL] [Abstract][Full Text] [Related]
32. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.
Misiewicz-Krzeminska I; Corchete LA; Rojas EA; Martínez-López J; García-Sanz R; Oriol A; Bladé J; Lahuerta JJ; Miguel JS; Mateos MV; Gutiérrez NC
Haematologica; 2018 May; 103(5):880-889. PubMed ID: 29545347
[TBL] [Abstract][Full Text] [Related]
33. Insights from the gene expression profiling of multiple myeloma.
Claudio JO; Masih-Khan E; Stewart AK
Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
[TBL] [Abstract][Full Text] [Related]
34. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
[TBL] [Abstract][Full Text] [Related]
35. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines.
Jiang H; Gao W; Sze DM; Xiong H; Hou J
Int J Hematol; 2007 Dec; 86(5):429-37. PubMed ID: 18192112
[TBL] [Abstract][Full Text] [Related]
36. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
37. The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance.
Chen R; Zhao H; Wu D; Zhao C; Zhao W; Zhou X
Oncotarget; 2016 Nov; 7(45):73101-73113. PubMed ID: 27683032
[TBL] [Abstract][Full Text] [Related]
38. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
39. The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?
Höllein A; Twardziok SO; Walter W; Hutter S; Baer C; Hernandez-Sanchez JM; Meggendorfer M; Haferlach T; Kern W; Haferlach C
Cancer Genet; 2020 Apr; 242():15-24. PubMed ID: 31980417
[TBL] [Abstract][Full Text] [Related]
40. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
